POLE and neoplasm: Therefore, regardless of how technically robust biomarkers such as MSI/MSS status, TMB, PDL1, POLE/POLD1 mutation, and MSI-like gene signature, these biomarkers will only characterize the quantity of tumor-infiltrating CD8+ T cells.